Trials / Completed
CompletedNCT01015235
Safety and Efficacy Study of KAI-1678 to Treat Subjects With Postoperative Pain
A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion for the Treatment of Postoperative Pain
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- KAI Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether KAI-1678 is effective in the treatment of postoperative pain following total hip or total knee replacement.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Subcutaneous infusion-once over 4 hours |
| DRUG | KAI-1678 | Subcutaneous infusion-once over 4 hours |
| DRUG | Ketorolac Tromethamine | Active comparator, IV infusion, once |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2010-02-01
- Completion
- 2010-02-01
- First posted
- 2009-11-18
- Last updated
- 2011-09-02
Locations
1 site across 1 country: New Zealand
Source: ClinicalTrials.gov record NCT01015235. Inclusion in this directory is not an endorsement.